MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Drug-induced parkinsonism(DIP)"

  • 2025 International Congress

    Drug-induced parkinsonism with resting tremor

    M. Nomoto, A. Watanabe (Imabari Ehime, Japan)

    Objective: Resting tremor might be developed by long-term treatment of dopamine receptor antagonists in cases of drug-induced parkinsonism Background: Resting tremor is one of the…
  • 2025 International Congress

    Parkinsonism following Chronic Disulfiram Overdose

    S. Ray, V. Kamath, B. Bairy (Bangalore, India)

    Objective: To describe the effect of chronic intake of disulfiram Background: Background- Drug induced parkinsonism is one of the commonest causes of non-degenerative parkinsonism. Typical…
  • 2025 International Congress

    Drug-induced Parkinsonism Mimicking Parkinson´s Disease in Patients Treated with Flunarizine for Migraine

    N. Guragain, R. Ojha, B. Gajurel, R. Karn, R. Rajbhandari (Kathmandu, Nepal)

    Objective: To understand the pattern of movement disorders caused by migraine prophylactic medicine such as flunarizine. Background: Migraine prophylactic treatments are usually taken for short…
  • 2025 International Congress

    Neuroprotective Role of Diosgenin-Loaded Lipid Nanoparticles for Parkinson’s Disease: Pharmacokinetic and Pharmacodynamic Insights

    R. Rajput, S. Verma (Agra, India)

    Objective: To develop, optimize, and evaluate diosgenin-loaded solid lipid nanoparticles (DG-SLNs) and nanostructured lipid carriers (DG-NLCs) incorporated into hydrogel formulations (DG-SLN-C and DG-NLC-C) for improved…
  • 2025 International Congress

    Cerebellar Syndrome and Parkinsonism Associated with Acquired Hepatocerebral Degeneration with Unusual Findings on Neuroimaging.

    R. Sanjinez, J. Bestoso (Buenos Aires, Argentina)

    Objective: To present a clinical case of cerebellar syndrome and parkinsonism linked to acquired hepatocerebral degeneration exhibiting atypical radiological abnormalities. Background: Acquired hepatocerebral degeneration (AHCD)…
  • 2025 International Congress

    Carvacrol modulates rotenone-induced Nigrostriatal Neuronal Death and Angiogenesis via targeting AMPK/FOXO3 transcription factor O3 Signaling cascade

    D. Singh (Allahabad, India)

    Objective: With an eye toward its effects on striatal angiogenesis and the AMPK/ FOXO3 transcription factor O3 pathway, this work attempts to investigate the neuroprotective…
  • 2025 International Congress

    40,000 Instrumented Timed-up-and-go Tests – Standardization is within Reach

    Z. Yekutieli, P. Lewitt (Tel Aviv, Israel)

    Objective: Timed-up-and-go (TUG) is a standard test in neurological assessment. TUG completion time is currently the only quantitative result reported and matched against age and…
  • 2024 International Congress

    Parkinson’s disease in a Special Population -Diagnosis and treatment of Parkinson’s disease in cases of psychiatric disorders treated with dopamine receptors antagonists-

    M. Nomoto, S. Oda, H. Doi (Imabari, Japan)

    Objective: We studied diagnosis and treatment of Parkinson’s disease in cases of psychiatric disorders treated with dopamine receptors antagonists for a long time. Background: Schizophrenia…
  • 2024 International Congress

    Association between Antiepileptic Drugs and Parkinson’s Disease: A Strong or Weak Link?

    S. Kharel, SS. Shrestha, SA. Acharya, R. Ojha (Kathmandu, Nepal)

    Objective: To perform a meta-analysis to show the association between different Antiepileptic Drugs(AEDs) and Parkinson’s disease(PD). Background: PD is a neurodegenerative disorder affecting 1-2% of…
  • 2024 International Congress

    Drug-Induced Parkinsonism and Tardive Dyskinesia in Rats Chronically Treated with Haloperidol

    H. Hikichi, H. Nishijima, F. Mori, I. Kinoshita, C. Murakami, M. Tomiyama (Hirosaki, Japan)

    Objective: To reproduce the side effects of antipsychotic drugs (drug-induced Parkinsonism and tardive dyskinesia) in rats and elucidate its pathomechanism by examining morphological changes in…
  • 1
  • 2
  • 3
  • …
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley